{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T00:56:02Z","timestamp":1648860962724},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2011,3,30]],"date-time":"2011-03-30T00:00:00Z","timestamp":1301443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Novartis Pharmaceuticals"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Significant advances in treatment and monitoring for patients with chronic myeloid leukemia have occurred over the last decade. With the introduction of the tyrosine kinase inhibitor imatinib, long-term outcomes have improved and new challenges, such as resistance, including mutations, have emerged. Research efforts into mutational analysis have intensified, with emphasis on the potential of using this technique to guide second-generation tyrosine kinase inhibitor selection. Although some data suggest that a small number of mutations may be associated with a less favorable response to treatment with one second-generation tyrosine kinase inhibitor versus another, these data need to be interpreted cautiously because they are derived primarily retrospectively from single-institution studies and a small number of patients. More research and clinical experience and a better understanding of the implications of in vitro data are needed before these data can be routinely incorporated into therapeutic decisions. Currently, there is no consensus on when to screen patients for mutations, what technique should be used, or how values should be reported. Selection of a second-generation tyrosine kinase inhibitor should therefore be based upon its toxicity profile in conjunction with the patient's comorbidities and the practitioner's experience.<\/jats:p>","DOI":"10.1634\/theoncologist.2010-0297","type":"journal-article","created":{"date-parts":[[2011,3,31]],"date-time":"2011-03-31T01:25:23Z","timestamp":1301534723000},"page":"554-558","source":"Crossref","is-referenced-by-count":0,"title":["Predictive Value of In Vitro Mutation Data to Guide Second-Generation Tyrosine Kinase Inhibitor Selection: Ready for Prime Time?"],"prefix":"10.1093","volume":"16","author":[{"given":"Richard T.","family":"Silver","sequence":"first","affiliation":[{"name":"Weill Cornell Medical College, Department of Medicine, Division of Hematology and Medical Oncology, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2011,3,30]]},"reference":[{"key":"2021122303324489500_B1","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/leu.2009.193","article-title":"Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: Weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history","volume":"24","author":"Jabbour","year":"2010","journal-title":"Leukemia"},{"key":"2021122303324489500_B2","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1586\/14737140.8.6.853","article-title":"Imatinib mesylate for the treatment of chronic myeloid leukemia","volume":"8","author":"Soverini","year":"2008","journal-title":"Expert Rev Anticancer Ther"},{"key":"2021122303324489500_B3","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1182\/blood.V114.22.1126.1126","article-title":"International randomized study of interferon and STI571 (IRIS) 8-year follow up: Sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib [abstract 1126]","volume":"114","author":"Deininger","year":"2009","journal-title":"Blood"},{"key":"2021122303324489500_B4","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","article-title":"Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia","volume":"110","author":"O'Hare","year":"2007","journal-title":"Blood"},{"key":"2021122303324489500_B5","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1182\/blood-2006-07-035493","article-title":"Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure","volume":"109","author":"Quint\u00e0s-Cardama","year":"2007","journal-title":"Blood"},{"key":"2021122303324489500_B6","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2009.25.4896","article-title":"Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase","volume":"28","author":"Cortes","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122303324489500_B7","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1200\/JCO.2009.21.8230","article-title":"Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase","volume":"27","author":"Hughes","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122303324489500_B8","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1182\/blood-2009-08-215939","article-title":"Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: Does the BCR-ABL mutation status really matter?","volume":"114","author":"Branford","year":"2009","journal-title":"Blood"},{"key":"2021122303324489500_B9","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.beha.2009.05.004","article-title":"Cause and management of therapy resistance","volume":"22","author":"Hochhaus","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"key":"2021122303324489500_B10","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1182\/blood-2009-04-214221","article-title":"Dasatinib treatment of chronic-phase chronic myeloid leukemia: Analysis of responses according to preexisting BCR-ABL mutations","volume":"114","author":"M\u00fcller","year":"2009","journal-title":"Blood"},{"key":"2021122303324489500_B11","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1200\/JCO.2008.19.8853","article-title":"Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR\/ABL mutants","volume":"27","author":"Redaelli","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122303324489500_B12","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1182\/blood-2009-01-197715","article-title":"Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations","volume":"114","author":"Jabbour","year":"2009","journal-title":"Blood"},{"key":"2021122303324489500_B13","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.1200\/JCO.2009.26.4945","article-title":"Comparative in vitro cellular data alone are insufficient to predict clinical responses and guide choice of BCR-ABL inhibitor for treating imatinib-resistant chronic myeloid leukemia","volume":"28","author":"Laneuville","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122303324489500_B14","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1182\/blood-2005-03-1036","article-title":"High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-na\u00efve patients: Correlation with clonal cytogenetic evolution but not response to therapy","volume":"106","author":"Willis","year":"2005","journal-title":"Blood"},{"key":"2021122303324489500_B15","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: An update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122303324489500_B16","volume-title":"The National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology\u2122. Chronic Myelogenous Leukemia. Version 2, 2010","author":"National Comprehensive Cancer Network","year":"2011"},{"key":"2021122303324489500_B17","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3324\/haematol.12588","article-title":"Monitoring treatment of chronic myeloid leukemia","volume":"93","author":"Baccarani","year":"2008","journal-title":"Haematologica"},{"key":"2021122303324489500_B18","first-page":"365","article-title":"BCR-ABL mutational studies for predicting the response of patients with chronic myeloid leukaemia to second-generation tyrosine kinase inhibitors after imatinib failure","volume":"15","author":"Kwan","year":"2009","journal-title":"Hong Kong Med J"},{"key":"2021122303324489500_B19","doi-asserted-by":"crossref","first-page":"7374","DOI":"10.1158\/1078-0432.CCR-06-1516","article-title":"Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: By the GIMEMA Working Party on Chronic Myeloid Leukemia","volume":"12","author":"Soverini","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2021122303324489500_B20","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1182\/blood-2004-03-1114","article-title":"Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment","volume":"105","author":"Chu","year":"2005","journal-title":"Blood"},{"key":"2021122303324489500_B21","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/sj.leu.2404554","article-title":"Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib","volume":"21","author":"Sherbenou","year":"2007","journal-title":"Leukemia"},{"issue":"suppl 3","key":"2021122303324489500_B22","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1053\/j.seminhematol.2009.01.009","article-title":"Understanding the role of mutations in therapeutic decision making for chronic myeloid leukemia","volume":"46","author":"Jabbour","year":"2009","journal-title":"Semin Hematol"},{"key":"2021122303324489500_B23","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1182\/blood-2007-09-110189","article-title":"Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: Practical advice on the use and interpretation of monitoring methods","volume":"111","author":"Kantarjian","year":"2008","journal-title":"Blood"},{"key":"2021122303324489500_B24","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood-2007-11-123950","article-title":"Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy","volume":"112","author":"Jabbour","year":"2008","journal-title":"Blood"},{"key":"2021122303324489500_B25","doi-asserted-by":"crossref","first-page":"905","DOI":"10.2174\/156802608784911635","article-title":"Inhibitors of ABL and the ABL-T315I mutation","volume":"8","author":"Noronha","year":"2008","journal-title":"Curr Top Med Chem"},{"key":"2021122303324489500_B26","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/leu.2008.47","article-title":"Experimental non-ATP-competitive therapies for chronic myelogenous leukemia","volume":"22","author":"Quint\u00e0s-Cardama","year":"2008","journal-title":"Leukemia"},{"key":"2021122303324489500_B27","doi-asserted-by":"crossref","first-page":"5382","DOI":"10.1002\/cncr.24601","article-title":"Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009","volume":"115","author":"Quint\u00e0s-Cardama","year":"2009","journal-title":"Cancer"},{"key":"2021122303324489500_B28","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/978-3-642-01222-8_14","article-title":"Danusertib (formerly PHA-739358)\u2014a novel combined pan-Aurora kinases and third generation Bcr-Abl tyrosine kinase inhibitor","volume":"184","author":"Gontarewicz","year":"2010","journal-title":"Recent Results Cancer Res"},{"key":"2021122303324489500_B29","first-page":"1","article-title":"ODAC votes against Cell Therapeutics agent; requires ChemGenex to develop diagnostic","volume":"36","year":"2010","journal-title":"Cancer Lett"},{"key":"2021122303324489500_B30","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.312.7023.71","article-title":"Evidence based medicine: What it is and what it isn't","volume":"312","author":"Sackett","year":"1996","journal-title":"BMJ"},{"key":"2021122303324489500_B31","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1001\/jama.296.9.1192","article-title":"JAMA patient page. Evidence-based medicine","volume":"296","author":"Torpy","year":"2006","journal-title":"JAMA"},{"key":"2021122303324489500_B32","first-page":"1517","article-title":"An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: Developed for the American Society of Hematology","volume":"94","author":"Silver","year":"1999","journal-title":"Blood"},{"key":"2021122303324489500_B33","volume-title":"Systematic Reviews on Selected Pharmacogenetics Tests for Cancer Treatment: CYP2D6 for Tamoxifen in Breast Cancer, KRAS for Anti-EGFR Antibodies in Colorectal Cancer, and BCR-ABL1 for Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia, 2\/10 version","author":"Agency for Healthcare Research and Quality","year":"2011"},{"key":"2021122303324489500_B34","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3324\/haematol.11993","article-title":"Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib","volume":"93","author":"Ernst","year":"2008","journal-title":"Haematologica"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2010-0297","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2010-0297","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/16\/5\/554\/41853363\/oncolo_16_5_554.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/16\/5\/554\/41853363\/oncolo_16_5_554.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T05:22:22Z","timestamp":1640236942000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/16\/5\/554\/6400751"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,30]]},"references-count":34,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2011,3,30]]},"published-print":{"date-parts":[[2011,5,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2010-0297","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2011,5,1]]},"published":{"date-parts":[[2011,3,30]]}}}